Drug intelligence / Profile preview

CB34

Development stage: Preclinical
Modality: Small Molecules

Overview

CB34 is a small molecule that acts as an agonist for the translocator protein 18 kDa (TSPO), formerly known as the peripheral benzodiazepine receptor. In preclinical studies, CB34 has been shown to inhibit the effect of the TSPO antagonist ONO-2952 on stress-induced noradrenaline release in rats. It also increases the formation of neuroactive steroids in plasma and brain, which in turn can indirectly modulate GABA(A) receptor activity, suggesting a role in mediating specific central effects of ethanol and potentially in stress-related disorders.

Targets

TSPO (Translocator Protein (18 kDa))

Beyond the preview

Go deeper on CB34.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CB34.

Explore the full profile